I believe the Market is digesting this news BUT in the end Triferic is a better safer more effective less expensive treatment.............at some point the dialysis business has to evolve and offer advancment in iron delivery................ im hanging in thereand wont start trimming my position till we hit $20
Sentiment: Strong Buy
Rockwell Medical: Disruption in Progress
By Jonathan Moreland
Safe, boring businesses can be vulnerable to disruptive technology. Rockwell Medical (NASDAQ:RMTI) is both safe and potentially disruptive, and looks like a good bet to alter the staid dialysis business from within.
Rockwell is one of only two major suppliers of dialysate (a chemical used in dialysis) in the US. Unfortunately, this stable business is not particularly profitable due to pricing pressure from much larger competitor, Fresenius (NYSE:FMS). Caps on reimbursement from Medicare and Medicaid for dialysate don’t help either.
Rockwell’s dialysate business has, however, opened a valuable channel for this trusted supplier to sell related, higher-margin products through to a very concentrated customer base. That’s what Rockwell has been focused on doing for years, and the risks of its past efforts are finally translating into rewards for shareholders via two new products: Triferic and Calcitriol.
Triferic is a potentially disruptive drug that replaces the need for iron to be intravenously delivered into dialysis patients. It has both clinical benefits for patients, and economic benefits to dialysis providers by reducing the need for costlier drugs now used in the process.
Both the efficacy and safety of Triferic were clearly shown by clinical trials that wrapped up last summer. Rockwell can now file a new drug application (NDA) for Triferic in early 2014, with expectations of getting the drug in place to attack a $600 million annual market opportunity by the end of 2014.
Rockwell also looks likely to get its new generic vitamin D product, Calcitriol, to market by the end of 2013. All that‘s left in the process is to receive FDA manufacturing approval. Calcitriol is also used in dialysis, and it’s the lowest cost option around, targeting a larger market estimated at $350 million per year.
I bought into Rockwell in early August 2013 for its sum-of-the-business value, after a troika of insiders wi
Calcitrol and Triferic approvals.............$40
FDA slams all of the above...................$4
I'm betting on $40 !
even missing earnings is understood as insignificant VS the potential. Triferic is a GAME CHANGER and safer than current IV Iron delivery......................ANY QUESTIONS !?
Hello Hyman I would like your opinion on ACRX short and long term please I am a LONG RMTI holder and know what im looking to get out of it dont know enough about ACRX
certainly we all agree that the potential is much higher than $20. SFP is a game changer and so far so good. the buyout potential once this products launches and is well recieved in much much higher than $20
without getting blindsided along the way I think we see $20 within 6 monhts